The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1409
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a once-daily, extended-release oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution (Methylin, and generics) has been available since 2003.1

METHYLPHENIDATE — All methylphenidate products are schedule II controlled substances. Short-acting methylphenidate is effective for treatment of ADHD, but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing. Long-acting methylphenidate preparations with once-daily dosing have therefore become the mainstay of clinical practice. Most long-acting formulations are available only as tablets or capsules and many children find these difficult to swallow. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
Article code: 1409b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian